Organisation paid for research Program year 2023 Source: CMS Open Payments

Clinical Research Services

Neither a doctor nor a teaching hospital

Research payments

$390,546

12 payments

Through program year 2023, Clinical Research Services is reported as receiving $390,546 in research payments, across 12 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$160,425	3
2022	Research	$115,750	4
2021	Research	$114,371	5

Breakdown

Who paid Research payments · program years 2021–2023

Celgene Corporation $183,238 6 payments
Takeda Pharmaceuticals U.S.A., Inc. $135,843 2 payments
G1 Therapeutics, Inc. $71,465 4 payments

Studies the money was for Research payments · program years 2021–2023

An oral inhibitor of tyrosine kinase 2 (TYK2) that binds to the JH2 pseudokinase domain, resulting in highly selective TYK2 kinase activity compared with the other homologous proteins in the Janus kinase (JAK) family of nonreceptor tyrosine kinases (JAK1, JAK2, and JAK3) $135,843 2 payments
A Phase 1, Open-Label, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects with Moderate and Severe Hepatic Impairment Compared with Healthy Subjects $77,555 1 payment
A Phase 1 Open-Label Single-Dose Study to Assess t $37,604 1 payment
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) $36,177 2 payments
G1t28-113 $35,289 2 payments
A Phase 1, Open-Label, Single Dose Study to Assess $33,605 1 payment
A Phase 1 Open-label, Single-dose Study to Assess $27,051 1 payment
Hepatic (RPC-1063-CP-004) (BMS Study Number: IM047-P06) $5,405 1 payment
Hepatic Impairment CC-90007-CP-007 $2,018 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.